Advertisement

CNS Drugs

, Volume 32, Issue 12, pp 1183–1183 | Cite as

Correction to: Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis

  • Mark Gudesblatt
  • Karl Wissemann
  • Myassar Zarif
  • Barbara Bumstead
  • Lori Fafard
  • Jeffrey Wilken
  • Karen Blitz
  • Marijean Buhse
  • Sourav Santra
  • Christophe Hotermans
  • Lily Lee
Correction

1 Correction to: CNS Drugs  https://doi.org/10.1007/s40263-018-0553-1

An Online First version of this article was made available online at http://link.springer.com/journal/40263/onlineFirst/page/1 on 24 August 2018. An error was subsequently identified in the article, and the following correction should be noted:

Author listing: The name of the second author, which previously read:

‘Karl Wisseman’

Should read:

‘Karl Wissemann’.

The original article has been corrected.

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Mark Gudesblatt
    • 1
  • Karl Wissemann
    • 1
  • Myassar Zarif
    • 1
  • Barbara Bumstead
    • 1
  • Lori Fafard
    • 1
  • Jeffrey Wilken
    • 2
  • Karen Blitz
    • 1
  • Marijean Buhse
    • 1
  • Sourav Santra
    • 3
  • Christophe Hotermans
    • 3
  • Lily Lee
    • 3
  1. 1.South Shore Neurologic AssociatesPatchogueUSA
  2. 2.Washington Neuropsychology Research Group LLCFairfaxUSA
  3. 3.BiogenCambridgeUSA

Personalised recommendations